In 2009 Trevor Hansel became Medical Director of the Imperial Clinical Respiratory Research Unit (ICRRU) at St Mary's Hospital, having been Medical Director of the NHLI Clinical Studies Unit at the Royal Brompton Hospital from 1997-2009. He is also an Honorary Consultant Immunologist at St. Mary's Hospital in London.
He obtained his medical degree in 1982 at the Welsh National School of Medicine, Cardiff and then completed higher specialist medical training in clinical immunology in Birmingham. From 1990-1993 Trevor performed clinical asthma research in Davos, Switzerland; developing methods for blood eosinophil isolation and sputum eosinophil surface marker assessment. Following this, he worked in respiratory drug development with Sandoz and Roche in Basel; working in project management and clinical development. In addition, he has regulatory experience from the Biotechnology Unit of the Medicines Control Agency (MCA) in London.
Trevor has a specialist interest in phase II clinical testing of new anti-inflammatory therapies for asthma and COPD, and has worked on a variety of challenge models in patients. In particular he is working on novel non-invasive methods to sample the airways: using synthetic absorptive matrices to measure cytokines and chemokines in nasal and bronchial mucosal lining fluid. These sampling methods have been developed on nasal allergen challenge, and he is also working on challenges with viruses, cigarette smoke, and agonists for innate immunity (LPS and poly-IC). He also works on human whole blood challenge methods to demonstrate pharmacodynamic activity of anti-inflammatory drugs.
Trevor Hansel has close collaborations with colleagues at Imperial: including Jane Mitchell, Peter Openshaw, Seb Johnston, Ajit Lalvani, Robin Shattock, Onn Min Kon, Julian Jones, Zoltan Takats.
Trevor Hansel and Peter Barnes are authors of "An Atlas of COPD" (Parthenon, 2004) and also together edited "New Drugs for Asthma, Allergy and COPD" (Karger, 2001 and 2010). They also co-organise regular conferences on “New Drugs for Asthma and COPD” at the Royal Brompton Hospital.
• To further develop novel methods of sampling the airways: by absorption, cell binding and curettage.
• In particular he is currently involved in a NIHR BRC project that develops a series of nasal challenges in man.
• To use these sampling and challenge methods in patients to develop biomarkers, identify novel targets for drugs, and test new anti-inflammatory therapies.
et al., 2017, The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms., J Allergy Clin Immunol
et al., 2017, Mucosal Type 2 Innate Lymphoid Cells Are a Key Component of the Allergic Response to Aeroallergens, American Journal of Respiratory and Critical Care Medicine, Vol:195, ISSN:1073-449X, Pages:1586-1596
et al., 2017, A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-gamma and IFN-lambda) and Type 2 Inflammation (IL-5 and IL-13), Ebiomedicine, Vol:19, ISSN:2352-3964, Pages:128-138
et al., 2017, Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis, Journal of Infectious Diseases, Vol:215, ISSN:0022-1899, Pages:1240-1244
et al., 2017, The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1b), and complement, Mucosal Immunology, Vol:10, ISSN:1933-0219, Pages:408-420